Details

Autor(en) / Beteiligte

• Mahal, Brandon A
• Ziehr, David R
• Aizer, Ayal A
• Hyatt, Andrew S
• Lago-Hernandez, Carlos
• Choueiri, Toni K
• Elfiky, Aymen A
• Hu, Jim C
• Sweeney, Christopher J
• Beard, Clair J
• D’Amico, Anthony V
• Martin, Neil E
• Kim, Simon P
• Lathan, Christopher S
• Trinh, Quoc-Dien
• Nguyen, Paul L

Titel

Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer

Ist Teil von

• Journal of geriatric oncology, 2014-10, Vol.5 (4), p.352-358

Ort / Verlag

Netherlands: Elsevier Ltd

Erscheinungsjahr

2014

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• Abstract Purpose To evaluate the relationship between age and race on the receipt of definitive therapy among men with high-risk prostate cancer (CaP). Methods We used the Surveillance, Epidemiology and End Results Program to identify 62,644 men with high-risk CaP (PSA > 20 or Gleason 8–10 or stage ≥ cT3a) diagnosed from 2004 to 2010. Multivariable logistic regression analysis modeled the interaction between age and race and its association with receipt of definitive therapy on 57,674 patients (47,879 white men; 9,795 African American [AA] men) with complete data on the covariates of interest. Results Among men age ≥ 70, AA men had a higher risk of CaP-specific mortality (PCSM) compared to white men after adjusting for sociodemographic and prostate cancer-specific factors (Adjusted HR 1.20; 95% CI 1.02–1.38; P = 0.02). Nevertheless, a significant interaction between race and age was found ( Pinteraction = 0.01), such that the adjusted odds of receiving definitive treatment for AA vs. white was 0.67 (95% CI 0.62–0.73; P < 0.001) among men age < 70, but was 0.60 (95% CI 0.55–0.66; P < 0.001) among men age ≥ 70, suggesting increased racial disparity in the receipt of definitive treatment among older men. Conclusion AA men with high-risk CaP are less likely to receive definitive therapy than white men. This disparity is significantly larger among men age ≥ 70, despite excess PCSM among AA men in this group. With a rapidly expanding population of older minority men, this disparity should be urgently addressed to prevent increasing disparities in cancer care.